<li>artemether/lumefantrine<p>artemether/lumefantrine will increase the level or effect of morphine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.</p></li><li>buprenorphine<p>buprenorphine, morphine. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.</p></li><li>buprenorphine buccal<p>buprenorphine buccal, morphine. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.</p></li><li>butorphanol<p>butorphanol, morphine. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.</p></li><li>cimetidine<p>cimetidine increases effects of morphine by decreasing metabolism. Avoid or Use Alternate Drug.</p></li><li>citalopram<p>morphine, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>desvenlafaxine<p>morphine and desvenlafaxine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>eluxadoline<p>morphine, eluxadoline.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions. .</p></li><li>escitalopram<p>morphine, escitalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fentanyl<p>fentanyl, morphine.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension,  profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.</p></li><li>fentanyl intranasal<p>fentanyl intranasal, morphine.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension,  profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.</p></li><li>fentanyl iontophoretic transdermal system<p>fentanyl iontophoretic transdermal system, morphine.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension,  profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.</p></li><li>fentanyl transdermal<p>fentanyl transdermal, morphine.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension,  profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.</p></li><li>fentanyl transmucosal<p>fentanyl transmucosal, morphine.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension,  profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.</p></li><li>fluoxetine<p>fluoxetine will increase the level or effect of morphine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>morphine, fluoxetine.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fluvoxamine<p>morphine, fluvoxamine.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>isocarboxazid<p>isocarboxazid and morphine both increase  serotonin levels. Avoid or Use Alternate Drug.<span><br><br></span>isocarboxazid increases toxicity of morphine by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.</p></li><li>ivacaftor<p>ivacaftor increases levels of morphine by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.</p></li><li>linezolid<p>linezolid and morphine both increase  serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.<span><br><br></span>linezolid increases toxicity of morphine by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.</p></li><li>lumefantrine<p>lumefantrine will increase the level or effect of morphine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.</p></li><li>methylene blue<p>methylene blue and morphine both increase  serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue morphine (if possible) and monitor for CNS toxicity. Morphine may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.</p></li><li>nalbuphine<p>nalbuphine, morphine. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.</p></li><li>naltrexone<p>naltrexone decreases levels of morphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.</p></li><li>paroxetine<p>paroxetine will increase the level or effect of morphine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>morphine, paroxetine.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>pentazocine<p>pentazocine, morphine. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Mixed opiate agonist/antagonists usually produce additive sedation with narcotics; however, in narcotic addicted pts., the antagonist activity may provoke withdrawal Sx.</p></li><li>phenelzine<p>phenelzine and morphine both increase  serotonin levels. Avoid or Use Alternate Drug.<span><br><br></span>phenelzine increases toxicity of morphine by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.</p></li><li>procarbazine<p>procarbazine increases toxicity of morphine by unknown mechanism. Avoid or Use Alternate Drug. MAOIs may potentiate CNS depression and hypotension. Do not use within 14 days of MAOI use. .</p></li><li>quinidine<p>quinidine will increase the level or effect of morphine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.</p></li><li>rasagiline<p>rasagiline increases toxicity of morphine by unknown mechanism. Avoid or Use Alternate Drug. May cause additive CNS depression, drowsiness, dizziness or hypotension, so use with MAOIs should be cautious; lower initial dosages of the analgesic are recommended followed by careful titration. Avoid combination within 14 days of MAOI use.</p></li><li>selegiline transdermal<p>selegiline transdermal increases toxicity of morphine by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death.</p></li><li>sertraline<p>morphine, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>sodium oxybate<p>morphine, sodium oxybate.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Additive CNS depression.</p></li><li>tramadol<p>tramadol, morphine. Other (see comment). Avoid or Use Alternate Drug. 
Comment: Tramadol may reinitiate opiate dependence in pts. previously addicted to other opiates; it may also provoke withdrawal Sx. in pts. who are currently opiate dependent.</p></li><li>tranylcypromine<p>tranylcypromine and morphine both increase  serotonin levels. Avoid or Use Alternate Drug.<span><br><br></span>tranylcypromine increases toxicity of morphine by unknown mechanism. Avoid or Use Alternate Drug. Risk of hypotension, hyperpyrexia, somnolence, or death; separate by 14 d.</p></li><li>valerian<p>valerian and morphine both increase  sedation. Avoid or Use Alternate Drug.</p></li><li>vortioxetine<p>morphine, vortioxetine.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li>